[go: up one dir, main page]

DE69634200D1 - Verfahren zur behandlung durch pneumocytis carini verursachten lungenentzündung und dafür geeignete verbindung - Google Patents

Verfahren zur behandlung durch pneumocytis carini verursachten lungenentzündung und dafür geeignete verbindung

Info

Publication number
DE69634200D1
DE69634200D1 DE69634200T DE69634200T DE69634200D1 DE 69634200 D1 DE69634200 D1 DE 69634200D1 DE 69634200 T DE69634200 T DE 69634200T DE 69634200 T DE69634200 T DE 69634200T DE 69634200 D1 DE69634200 D1 DE 69634200D1
Authority
DE
Germany
Prior art keywords
loweralkyl
alkylaminoalkyl
aminoalkyl
alkoxyalkyl
alkylaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69634200T
Other languages
English (en)
Other versions
DE69634200T2 (de
Inventor
R Tidwell
E Hall
W Boykin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Georgia State University Research Foundation Inc
Original Assignee
University of North Carolina at Chapel Hill
Georgia State University Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Georgia State University Research Foundation Inc filed Critical University of North Carolina at Chapel Hill
Application granted granted Critical
Publication of DE69634200D1 publication Critical patent/DE69634200D1/de
Publication of DE69634200T2 publication Critical patent/DE69634200T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
DE69634200T 1995-06-07 1996-06-03 Verfahren zur behandlung durch pneumocytis carini verursachten lungenentzündung und dafür geeignete verbindung Expired - Fee Related DE69634200T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/474,440 US5668166A (en) 1995-06-07 1995-06-07 Methods of inhibiting pneumocystis carinii pneumonia and compounds useful therefor
PCT/US1996/008464 WO1996040114A1 (en) 1995-06-07 1996-06-03 Methods of inhibiting pneumocystis carinii pneumonia and compounds useful therefor
US474440 1999-12-29

Publications (2)

Publication Number Publication Date
DE69634200D1 true DE69634200D1 (de) 2005-02-24
DE69634200T2 DE69634200T2 (de) 2005-11-17

Family

ID=23883544

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634200T Expired - Fee Related DE69634200T2 (de) 1995-06-07 1996-06-03 Verfahren zur behandlung durch pneumocytis carini verursachten lungenentzündung und dafür geeignete verbindung

Country Status (8)

Country Link
US (2) US5668166A (de)
EP (1) EP0831813B1 (de)
JP (1) JPH11506763A (de)
AT (1) ATE287263T1 (de)
AU (1) AU6148696A (de)
DE (1) DE69634200T2 (de)
ES (1) ES2236734T3 (de)
WO (1) WO1996040114A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935982A (en) * 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US6635668B1 (en) * 1998-07-22 2003-10-21 The University Of North Carolina At Chapel Hill Imidazoline receptor binding compounds
WO2000010990A2 (en) * 1998-08-20 2000-03-02 University Of North Carolina At Chapel Hill Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
JP2002524503A (ja) 1998-09-17 2002-08-06 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二陽イオン分子の抗真菌活性
EP1242059B1 (de) 1999-07-08 2007-03-21 University Of North Carolina At Chapel Hill Neue prodrugs für antimicrobielle amidine
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
AU1450401A (en) * 1999-11-01 2001-05-14 Auburn University Methods and formulations for the treatment of infectious bursal disease in avian subjects
US6774144B1 (en) 1999-11-01 2004-08-10 The University Of North Carolina At Chapel Hill Methods and formulations for the treatment of infectious bursal disease in avian subjects
EP1420773A1 (de) * 2001-08-31 2004-05-26 Neurochem (International) Limited Amidine derivate zur behandlung von amydosis
CN1886367A (zh) 2003-11-24 2006-12-27 北卡罗来纳大学查珀尔希尔分校 稠环双阳离子抗原生动物药物及其前药
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US7947741B2 (en) * 2004-03-17 2011-05-24 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
KR101233378B1 (ko) * 2009-05-08 2013-02-15 제일모직주식회사 유기광전소자용 화합물 및 이를 포함하는 유기광전소자
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061655A (en) * 1976-12-30 1977-12-06 E. R. Squibb & Sons, Inc. 3,6-Dicarboximidamidecarbazoles
US4963589A (en) * 1988-10-25 1990-10-16 The University Of North Carolina At Chapel Hill Methods for treating Giardia lamblia
US4933347A (en) * 1988-10-25 1990-06-12 University Of North Carolina At Chapel Hill Diamidines and bis(imidazolines) for the treatment of and prophylaxis against pneumocystis carinii pneumonia

Also Published As

Publication number Publication date
ATE287263T1 (de) 2005-02-15
DE69634200T2 (de) 2005-11-17
EP0831813B1 (de) 2005-01-19
EP0831813A4 (de) 2001-09-19
WO1996040114A1 (en) 1996-12-19
JPH11506763A (ja) 1999-06-15
AU6148696A (en) 1996-12-30
US5668167A (en) 1997-09-16
EP0831813A1 (de) 1998-04-01
ES2236734T3 (es) 2005-07-16
US5668166A (en) 1997-09-16

Similar Documents

Publication Publication Date Title
DE69634200D1 (de) Verfahren zur behandlung durch pneumocytis carini verursachten lungenentzündung und dafür geeignete verbindung
ATE207759T1 (de) Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels
ATE249228T1 (de) Verwendung von polyallylamin-polymeren zur herstellung eines medikamentes zur behandlung von hypercholesterolemia
ATE270553T1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren
EP0810884A4 (de) Verfahren zur behandlung von gefässthrombose und -restenose durch inhalieren von stickoxid
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
DE69729946D1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
EP0772439A4 (de) Neue antibiotika und verfahren zur behandlung von infektionen durch gram-positive bakterien und mykoplasmen
DE69735090D1 (de) Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen
ATE181235T1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
DE69515038D1 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69707033D1 (de) Verfahren zur Behandlung von Gasen die Organohalogenzusammensetzungen enthalten
DE69728819D1 (de) Einrichtung zur Behandlung von Atemgas eines intubierten Patienten
DE69112340D1 (de) Verfahren zur Behandlung von Abgasen die Halogenverbindungen enthalten.
DE69330282D1 (de) Chinolon und acridinon derivate zur behandlung der harninkontinenz
DE59209268D1 (de) Verfahren zur thermochemisch-thermischen behandlung von einsatzstählen
ATE99934T1 (de) Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
DE69630785D1 (de) Carbazole zur behandlung von mikrobiellen infektionen
DE69102294D1 (de) Verfahren zur Behandlung von Abgasen, die ClF3 enthalten.
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE169217T1 (de) Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten
DE69524479D1 (de) Verfahren zur Behandlung von sauren Abgasen
DE69301936D1 (de) Verfahren zur Behandlung von Rauchgas
DE60013326D1 (de) Verbindungen und verfahren zur behandlung von schmerz
DE69526584D1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie

Legal Events

Date Code Title Description
8380 Miscellaneous part iii

Free format text: DER VERTRETER IST ZU BERICHTIGEN IN: DIEHL & PARTNER, 80333 MUENCHEN

8364 No opposition during term of opposition
8380 Miscellaneous part iii

Free format text: DIE VERTRETER SIND ZU BERICHTIGEN IN: DIEHL & PARTNER, 80333 MUENCHEN

8339 Ceased/non-payment of the annual fee